Chronic pain patients enrolled in a statewide medical cannabis access program are significantly more likely to either reduce or cease their use of opioids as compared to non-enrolled patients suffering from similar pain conditions, according to data published online in the journal PLOS One.
A team of investigators at the University of New Mexico assessed opioid prescription use patterns over a 21-month period in 37 pain patients enrolled in the state’s medicinal cannabis program versus 29 non-enrolled patients.
Compared to non-users, medical cannabis enrollees “were more likely either to reduce daily opioid prescription dosages between the beginning and end of the sample period (83.8 percent versus 44.8 percent) or to cease filling opioid prescriptions altogether (40.5 percent versus 3.4 percent).” Enrollees were also more likely to report an improved quality of life.
Authors concluded, “The clinically and statistically significant evidence of an association between MCP enrollment and opioid prescription cessation and reductions and improved quality of life warrants further investigations on cannabis as a potential alternative to prescription opioids for treating chronic pain.”
Prior studies similarly report that patients enrolled in cannabis access programs are more likely to reduce their use of opioids and other prescription drugs.
Full text of the study, “Association between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study,” appears online here.
NORML’s marijuana and opioids fact-sheet is available online here.
